The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Abstract
Background: Baricitinib, an oral selective inhibitor of Janus kinase 1 and Janus kinase 2, modulates proinflammatory cytokine signaling. Objectives: The efficacy and safety of baricitinib were evaluated in patients with moderate‐to‐severe atopic dermatitis (AD). Methods: In this phase 2, randomized, double‐blind, placebo‐controlled study, 124 patients with moderate‐to‐severe AD applied topical corticosteroids (TCSs) for 4 weeks before randomization to once‐daily placebo, 2 mg of baricitinib, or 4 mg of baricitinib for 16 weeks. Use of TCSs was permitted during the study. The primary outcome was the proportion of patients achieving at least a 50% reduction in the Eczema Area and Severity Index (EASI‐50) compared with placebo. Results: Significantly more patients who received baricitinib, 4 mg, achieved EASI‐50 than did patients receiving placebo (61% vs 37% [P = .027]) at 16 weeks. The difference between the proportion of patients receiving baricitinib, 2 or 4 mg, who achieved EASI‐50 and the proportion of patients receiving placebo and achieving EASI‐50 was significant as early as week 4. Baricitinib also improved pruritus and sleep loss. Treatment‐emergent adverse events were reported in 24 of the patients receiving placebo (49%), 17 of those receiving 2 mg of baricitinib (46%), and 27 of those receiving 4 mg of baricitinib (71%). Limitations: A TCS standardization period before randomization reduced disease severity, limiting the ability to compare results with those of baricitinib monotherapy. Longer studies are required to confirm baricitinib's efficacy and safety in patients with AD. Conclusions: Baricitinib used with TCSs reduced inflammation and pruritus in patients with moderate‐to‐severe AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“TEAEs leading to discontinuation of treatment 5 (10) 1 (3) 5 (13) TEAEs occurring in $3 patients per treatment group, n (%) Headache 0 2 (5) 5 (13) Blood level of creatine phosphokinase increased 0 1 (3) 5 (13) Dermatitis, atopic 4 (8) 1 (3) 0 Nasopharyngitis 1 (2) 1 (3) 3 (8) Cellulitis 3 (6) 1 (3) 0 Lymphopenia 3 (6…”
Self-citationDupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A. M., Xu, A. Z., Tripathi, S. V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.006 · Cited by 1,092
Kunz, B., Oranje, A. P., Labrèze, L., Stalder, J.-F., Ring, J., & Taïeb, A. (1997) · Dermatology · doi:10.1159/000245677 · Cited by 1,046
The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch
Wilson, S. R., Thé, L., Batia, L. M., Beattie, K., Katibah, G. E., McClain, S. P., Pellegrino, M., Estandian, D. M., & Bautista, D. M. (2013) · Cell · doi:10.1016/j.cell.2013.08.057 · Cited by 987
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Charman, C. R., Venn, A. J., & Williams, H. C. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.12.1513 · Cited by 660
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Self-citationBaricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Fridman, J. S., Scherle, P. A., Collins, R., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B., Collier, P., Favata, M. F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902819 · Cited by 463
Fleischmann, R., Schiff, M., van der Heijde, D., Ramos‐Remus, C., Spindler, A., Stanislav, M., Zerbini, C. A. F., Gurbuz, S., Dickson, C., de Bono, S., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39953 · Cited by 427
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
Bissonnette, R., Papp, K. A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., Wang, C., Purohit, V., Mamolo, C., Papacharalambous, J., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14871 · Cited by 420
Dougados, M., van der Heijde, D., Chen, Y.-C., Greenwald, M., Drescher, E., Liu, J., Beattie, S., Witt, S., de la Torre, I., Gaich, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 404
Public Health Burden and Epidemiology of Atopic Dermatitis
Silverberg, J. I. (2017) · Dermatologic Clinics · doi:10.1016/j.det.2017.02.002 · Cited by 400 · cited 3×
“TEAE or serious adverse event during the treatment period, n (%) $1 TEAE 24 (49) 17 (46) 27 (71) $1 serious TEAE 0 0 1 (3)* TEAE resulting in death during treatment and follow-up period 0 0 0”
BackgroundSelf-citationWollenberg, A., Oranje, A., Deleuran, M., Simon, D., Szalai, Z., Kunz, B., Svensson, A., Barbarot, S., von Kobyletzki, L., Taieb, A., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13599 · Cited by 395
Papp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 327
Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation
Schmitt, J., Langan, S., Deckert, S., Svensson, A., von Kobyletzki, L., Thomas, K., & Spuls, P. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.008 · Cited by 292
van der Schaft, J., Politiek, K., van den Reek, J. M. P. A., Christoffers, W. A., Kievit, W., de Jong, E. M. G. J., Bruijnzeel-Koomen, C. A. F. M., Schuttelaar, M. L. A., & de Bruin-Weller, M. S. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13730 · Cited by 77
Yong, A. M.-Y., & Tay, Y. (2017) · Dermatologic Clinics · doi:10.1016/j.det.2017.02.012 · Cited by 69
Bieber, T. R. M., Akdiş, C. A., Lauener, R. P., Traidl‐Hoffmann, C., Schmid‐Grendelmeier, P., Schäppi, G., Allam, J., Apfelbacher, C., Augustin, M., Beck, L. A., et al. (2016) · Allergy · doi:10.1111/all.12857 · Cited by 59
Self-citationGene Therapy in a Patient with Sickle Cell Disease
Badat, M., & Davies, J. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1704009 · Cited by 56
Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster
Yamaoka, K. (2016) · Drug Safety · doi:10.1007/s40264-016-0430-0 · Cited by 39
Politiek, K., van der Schaft, J., Coenraads, P. J., de Bruin-Weller, M. S., & Schuttelaar, M. L. A. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13961 · Cited by 37
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
Egeberg, A., Thyssen, J. P., & Wu, J. J. (2017) · PubMed · doi:10.1056/nejmc1704013 · Cited by 12
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Pathophysiology of atopic dermatitis: Clinical implications
Kim, J., Kim, B. E., & Leung, D. Y. M. (2019) · Allergy and Asthma Proceedings · doi:10.2500/aap.2019.40.4202 · Cited by 635
Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C.-Y., Hong, H. C.-H., Katoh, N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00588-2 · Cited by 583
Self-citation
Metadata
- Authors
- Guttman-Yassky, E., Silverberg, J. I., Nemoto, O., Forman, S. B., Wilke, A., Prescilla, R., de la Peña, A., Nunes, F. P., Janes, J., Gamalo, M., Donley, D., Paik, J., DeLozier, A. M., Nickoloff, B. J., & Simpson, E. L.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 80
- Issue
- 4
- Pages
- 913-921.e9
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2787696154
- Cited by
- 317
- References
- 28
- FWCI
- 44.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.